Comedian Louis CK admitted sexually harassing women. Now he’s now staging a comeback – and women aren’t happy. In November 2017, five women came forward to publicly accuse American comedian ...

US comedian Louis CK has admitted that sexual misconduct allegations made against him by five women are true. He said he had "wielded power irresponsibly" and could hardly wrap his head around the ...

Louis CK's planned appearance on The Late Show with Stephen Colbert has also been cancelled US comedian Louis CK's movie premiere has been cancelled hours before the screening as five women ...

Louis Székely (born September 12, 1967), known professionally as Louis C.K., is an American stand-up comedian, Emmy-winning television and film writer, actor, producer, and director from Boston ...

HBO announced Thursday that Louie C.K. would no longer be appearing on its autism benefit shot, The Night of Too Many Stars, and it would remove all of the comedian's previous work from its on ...

Earnings Report 1.454 USD Q3 2024 Earnings Release 10/30/2024 Earnings Report 5.436 USD Q4 2024 Earnings Release 01/30/2025 Earnings Report 5.367 USD Q1 2025 Earnings Release 04/24/2025 Earnings ...

Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and ...

LEBANON, Ind. – Eli Lilly and Company will invest an additional $4.5 billion in Boone County to create a new center for advanced manufacturing and drug development. The Lilly Medicine Foundry ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to ...

Eli Lilly has become a household name thanks to breakthrough diabetes and obesity care medicines. The stock has trounced the broader market over the past year, and shares have become a bit pricey.

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.